论文部分内容阅读
观察几丁聚糖对高脂血症病人血浆脂质水平的影响。从门诊病人中筛选 31例高脂血症患者 ,试服几丁聚糖 2 g· d-1,服用 1mo,观察其临床降脂作用。同时通过腹部 B超及血清转氨酶测定 ,观察其对肝脏的影响。结果表明 :血清甘油三酯下降 32 .6% ( P<0 .0 5) ,血清胆固醇下降 12 .0 ( P<0 .0 1) ,低密度脂蛋白胆固醇下降 12 .8 ( P<0 .0 5) ,试服几丁聚糖前后 ,血清转氨酶均在正常范围内 ,肝脏 B超无明显改变。因此说明 ,几丁聚糖降血脂效果确切并且对肝脏功能无损害
Observe the effect of chitosan on plasma lipid levels in patients with hyperlipidemia. Thirty-one patients with hyperlipidemia were screened from outpatients and were given a dose of chitosan 2 g.d-1 for 1 month to observe their clinical lipid-lowering effects. At the same time, through abdominal B-ultrasound and serum transaminase determination, observe its impact on the liver. The results showed that serum triglycerides decreased by 32.6% (P<0.05), serum cholesterol decreased by 12.0% (P<0.01), and low-density lipoprotein cholesterol decreased by 12.8% (P< 0 .0 5) Before and after the trial of chitosan, serum transaminases were within the normal range, and there was no significant change in liver B-mode ultrasound. Therefore, it is shown that chitosan is effective in reducing blood lipids and has no damage to liver function.